Sanofi is continually assessing the global health implications of the COVID-19 virus and remain committed to working closely with global health organizations and governments to minimize the risk and impact of COVID-19.
We are very happy that they are taking precautions themselves, forgoing in-person meetings for the foreseeable future. Like most companies at this time, many are working from home or following general guidance from the Canadian health authorities.
At this time, Sanofi does not anticipate shortages for patients resulting from the COVID-19 situation. Sanofi is working to maintain the supply of all of of their medicines through close collaboration with suppliers throughout the world. We don’t expect there to be any issues at this time in regard to Myozyme infusions or clinical trials. If you have any concerns, please contact your doctor as the situation around home or hospital/clinic infusions could depend on the region you live in.
Please visit Sanofi.ca for more details.